U.S. Stock Futures Lower, Focus on Four Key Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- CoreWeave Agreement Expansion: CoreWeave has signed a long-term agreement valued at approximately $21 billion with Meta Platforms, extending through December 2032, which will bolster Meta's AI development by enhancing its inference workload capabilities and solidifying their partnership.
- Chevron Production Decline: Chevron reported a first-quarter production drop to an average of 3.8 to 3.9 million barrels of oil equivalent per day, down from 4.05 million boe/day in Q4, primarily due to the Middle East conflict and downtime at the Tengizchevroil project, although higher oil prices have helped upstream earnings.
- Eli Lilly Drug Launch: Eli Lilly announced that its newly approved weight loss pill, Foundayo, will be available in U.S. retail pharmacies starting today, intensifying competition with Novo Nordisk's Wegovy, which could impact market dynamics significantly.
- Tesla New Model Development: Tesla is reportedly developing a smaller, lower-cost electric SUV, still in early stages without production approval, but the company has begun discussions with suppliers, indicating its ongoing commitment to innovation in the electric vehicle market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 953.300
Low
950.00
Averages
1192
High
1500
Current: 953.300
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Foundayo Receives FDA Approval and Launches Nationwide
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
See More
Weight Watchers Stock Soars 15% in Premarket Trading Following Launch of Eli Lilly's New Oral Medication
- Stock Market Reaction: Weight Watchers shares surged by 15% in pre-market trading following the launch of their new oral drug.
- Product Launch Impact: The significant increase in stock value indicates positive investor sentiment towards the new product offering by Weight Watchers.
See More
Amazon Pharmacy Launches Eli Lilly's Weight Loss Pill Foundayo Nationwide
- Drug Availability: Amazon Pharmacy announced the availability of Eli Lilly's newly approved weight loss pill, Foundayo, in nearly 3,000 cities and towns across the U.S. through its same-day delivery service, significantly enhancing drug accessibility to meet the growing demand for weight loss solutions.
- Pricing Strategy: Cash-paying customers can purchase the medication at $5 per day or $149 per month with a valid prescription, while insured customers benefit from a lower price of $1 per day or $25 per month, showcasing Amazon's competitive edge in pharmaceutical pricing.
- Convenient Purchase Channels: Patients can also buy the GLP-1 therapy at in-office kiosks available at select One Medical locations shortly after medical appointments, further enhancing patient convenience and increasing Amazon's market penetration in the healthcare sector.
- Expansion Plans: Amazon aims to expand its same-day delivery service to nearly 4,500 U.S. localities by the end of the year, indicating its ongoing investment in pharmaceutical delivery services and proactive response to market demand.
See More
U.S. Stock Futures Lower, Focus on Four Key Stocks
- CoreWeave Agreement Expansion: CoreWeave has signed a long-term agreement valued at approximately $21 billion with Meta Platforms, extending through December 2032, which will bolster Meta's AI development by enhancing its inference workload capabilities and solidifying their partnership.
- Chevron Production Decline: Chevron reported a first-quarter production drop to an average of 3.8 to 3.9 million barrels of oil equivalent per day, down from 4.05 million boe/day in Q4, primarily due to the Middle East conflict and downtime at the Tengizchevroil project, although higher oil prices have helped upstream earnings.
- Eli Lilly Drug Launch: Eli Lilly announced that its newly approved weight loss pill, Foundayo, will be available in U.S. retail pharmacies starting today, intensifying competition with Novo Nordisk's Wegovy, which could impact market dynamics significantly.
- Tesla New Model Development: Tesla is reportedly developing a smaller, lower-cost electric SUV, still in early stages without production approval, but the company has begun discussions with suppliers, indicating its ongoing commitment to innovation in the electric vehicle market.
See More
US Stocks Surge Amid AI Company Blacklisting Controversy
- Strong Market Performance: The Dow Jones Industrial Average surged over 1,300 points yesterday, marking its best day of the year, despite Iran's accusations against the U.S. for breaching the ceasefire agreement, reflecting market optimism about economic recovery.
- AI Company Blacklisting Controversy: Anthropic's attempt to temporarily block its blacklisting by the Department of Defense was denied by a federal appeals court, indicating increasing government scrutiny over AI technologies, which may impact market confidence in related firms.
- Fed Rate Cut Expectations: Minutes from the Federal Reserve's meeting revealed that officials still expect to cut interest rates this year despite uncertainties, with market-implied odds of a cut rising to 43%, potentially stimulating investor risk appetite.
- Meta AI Model Launch: Meta debuted its first major AI model, Muse Spark, signaling a strategic shift in its approach to the AI market, and despite facing fierce competition, this new product could open up new revenue streams for the company.
See More
Weight Watchers Introduces Eli Lilly's New Oral GLP-1 Foundayo® via LillyDirect
Product Launch: Weight Watchers has launched a new oral GLP-1 medication called Dayo® through its subsidiary, LILLY.
Availability: The new medication is available directly through the LILLY platform, expanding Weight Watchers' offerings in weight management solutions.
See More
Foundayo Receives FDA Approval and Launches Nationwide
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
See More
Weight Watchers Stock Soars 15% in Premarket Trading Following Launch of Eli Lilly's New Oral Medication
- Stock Market Reaction: Weight Watchers shares surged by 15% in pre-market trading following the launch of their new oral drug.
- Product Launch Impact: The significant increase in stock value indicates positive investor sentiment towards the new product offering by Weight Watchers.
See More
Amazon Pharmacy Launches Eli Lilly's Weight Loss Pill Foundayo Nationwide
- Drug Availability: Amazon Pharmacy announced the availability of Eli Lilly's newly approved weight loss pill, Foundayo, in nearly 3,000 cities and towns across the U.S. through its same-day delivery service, significantly enhancing drug accessibility to meet the growing demand for weight loss solutions.
- Pricing Strategy: Cash-paying customers can purchase the medication at $5 per day or $149 per month with a valid prescription, while insured customers benefit from a lower price of $1 per day or $25 per month, showcasing Amazon's competitive edge in pharmaceutical pricing.
- Convenient Purchase Channels: Patients can also buy the GLP-1 therapy at in-office kiosks available at select One Medical locations shortly after medical appointments, further enhancing patient convenience and increasing Amazon's market penetration in the healthcare sector.
- Expansion Plans: Amazon aims to expand its same-day delivery service to nearly 4,500 U.S. localities by the end of the year, indicating its ongoing investment in pharmaceutical delivery services and proactive response to market demand.
See More
U.S. Stock Futures Lower, Focus on Four Key Stocks
- CoreWeave Agreement Expansion: CoreWeave has signed a long-term agreement valued at approximately $21 billion with Meta Platforms, extending through December 2032, which will bolster Meta's AI development by enhancing its inference workload capabilities and solidifying their partnership.
- Chevron Production Decline: Chevron reported a first-quarter production drop to an average of 3.8 to 3.9 million barrels of oil equivalent per day, down from 4.05 million boe/day in Q4, primarily due to the Middle East conflict and downtime at the Tengizchevroil project, although higher oil prices have helped upstream earnings.
- Eli Lilly Drug Launch: Eli Lilly announced that its newly approved weight loss pill, Foundayo, will be available in U.S. retail pharmacies starting today, intensifying competition with Novo Nordisk's Wegovy, which could impact market dynamics significantly.
- Tesla New Model Development: Tesla is reportedly developing a smaller, lower-cost electric SUV, still in early stages without production approval, but the company has begun discussions with suppliers, indicating its ongoing commitment to innovation in the electric vehicle market.
See More
US Stocks Surge Amid AI Company Blacklisting Controversy
- Strong Market Performance: The Dow Jones Industrial Average surged over 1,300 points yesterday, marking its best day of the year, despite Iran's accusations against the U.S. for breaching the ceasefire agreement, reflecting market optimism about economic recovery.
- AI Company Blacklisting Controversy: Anthropic's attempt to temporarily block its blacklisting by the Department of Defense was denied by a federal appeals court, indicating increasing government scrutiny over AI technologies, which may impact market confidence in related firms.
- Fed Rate Cut Expectations: Minutes from the Federal Reserve's meeting revealed that officials still expect to cut interest rates this year despite uncertainties, with market-implied odds of a cut rising to 43%, potentially stimulating investor risk appetite.
- Meta AI Model Launch: Meta debuted its first major AI model, Muse Spark, signaling a strategic shift in its approach to the AI market, and despite facing fierce competition, this new product could open up new revenue streams for the company.
See More
Weight Watchers Introduces Eli Lilly's New Oral GLP-1 Foundayo® via LillyDirect
Product Launch: Weight Watchers has launched a new oral GLP-1 medication called Dayo® through its subsidiary, LILLY.
Availability: The new medication is available directly through the LILLY platform, expanding Weight Watchers' offerings in weight management solutions.
See More
